Drug intelligence / Profile preview

hydroxyurea + magnesium chloride

Development stage: Approved
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of hydroxyurea and magnesium chloride. Hydroxyurea is an antimetabolite that works by inhibiting ribonucleotide reductase, an enzyme required for DNA synthesis, while also increasing fetal hemoglobin (HbF) levels in red blood cells. Magnesium chloride has antioxidant properties and helps stabilize red blood cell membranes. This combination has been studied primarily for beta-thalassemia intermedia, where it has shown improved efficacy in enhancing hematologic parameters and cardiac function compared to hydroxyurea alone.

Targets

RRM2

Beyond the preview

Go deeper on hydroxyurea + magnesium chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydroxyurea + magnesium chloride.

Explore the full profile